Company Overview of PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing drugs for endocrine and metabolic disorders, and cardiovascular disease. Its products include PB1023 for the treatment of hyperglycemia associated with type 2 diabetes, as well as with a potential for future use in the treatment of obesity; Insumera, a basal insulin ELP-fusion; and Vasomera, a vasoactive intestinal peptide agonist for acute and chronic heart failure and pulmonary arterial hypertension. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and it changed its name in November 2008. The company was founded in 2002 and is based in Malvern, Pennsylvania.
One Great Valley Parkway
Malvern, PA 19355
Founded in 2002
Key Executives for PhaseBio Pharmaceuticals, Inc.
Chief Executive Officer and Director
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.
PhaseBio Pharmaceuticals, Inc. Key Developments
PhaseBio Expands Clinical Development of Vasomera
Jun 18 13
PhaseBio Pharmaceuticals, Inc. announced the successful completion of a Phase 1 trial of Vasomera(TM) (PB1046), the first once-weekly investigational, VPAC2 selective receptor agonist for the treatment of cardiopulmonary diseases. This multi-center, randomized, double-blind, placebo-controlled trial demonstrated the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) response of single ascending subcutaneous (SC) doses of Vasomera in 40 patients. Trial results showed PD activity that was supportive of a once-weekly dosing regimen that could allow for chronic use in a home setting. In this Phase 1 trial, Vasomera was generally well tolerated with no clinically relevant cardiovascular safety signals identified. The Company plans to submit the full data set to an upcoming major medical meeting. Based on the clinical results of the Phase 1 trial evaluating SC Vasomera, PhaseBio has initiated a second Phase 1 trial to evaluate the safety, tolerability and PK/PD response of single ascending doses of short-term IV-infused Vasomera. IV administration of Vasomera would enable use in an acute hospital setting, with the goal of preserving or improving hemodynamic function in heart failure and reducing the incidence of re-hospitalization. The trial is expected to enroll up to 32 patients and will evaluate the acute impact of Vasomera on hemodynamic function using echocardiographic analyses. It will also provide support for the development of Vasomera for treatment of acute heart failure as well as pulmonary arterial hypertension (PAH). The trial is expected to complete in the third quarter of 2013.
PhaseBio Pharmaceuticals, Inc. Initiates Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes
Jun 4 13
PhaseBio Pharmaceuticals, Inc. announced that it has initiated the first Phase 1 study for development of PE0139, a novel long-acting basal insulin, for the treatment of Type 2 diabetes. This single ascending dose, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetic (PK) pharmacodynamic (PD) profile of PE0139 in people living with Type 2 diabetes. The study will also assess the duration of glycemic control _ up to one week _ of the investigational compound. PE0139 is a fully human monomeric insulin fused to an elastin like polypeptide (ELP), PhaseBio's proprietary biopolymer platform.
PhaseBio Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-05-2013 12:30 PM
May 21 13
PhaseBio Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-05-2013 12:30 PM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Jonathan Mow, Chief Business Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|